A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis
Phase 3
Terminated
NCT05265728
| Condition | Multiple Sclerosis, Relapsing-Remitting |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Biogen |
|---|
| Status | Terminated |
|---|
| Enrollment | 21 participants |
|---|
| Interventions | Natalizumab |
|---|
| Start date | Apr 26, 2022 |
|---|
| Completion date | Jan 18, 2024 |
|---|
| Results posted | Nov 25, 2025 |
|---|
Summary
The primary objective of this study is to evaluate the efficacy of natalizumab 300 milligrams (mg) subcutaneous (SC) every 4 weeks (Q4W) administrations up to 24 weeks in Japanese participants with relapsing-remitting multiple sclerosis (RRMS). The secondary objectives of the study are to evaluate other clinical and magnetic resonance imaging (MRI) measures of efficacy of natalizumab 300 mg SC Q4W administrations in Japanese participants with RRMS, to evaluate the safety, tolerability, and immunogenicity of natalizumab 300 mg SC Q4W administrations up to 48 weeks in Japanese participants with RRMS, to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of natalizumab 300 mg SC Q4W administrations up to 24 weeks and for an additional 24 weeks in Japanese participants with RRMS.
Part 1: Cumulative Number of New Active Lesions up to Week 24 Identified Using Brain Magnetic Resonance Imaging (MRI) Scans
Up to Week 24 · number of lesions
| Natalizumab | 0.4 ± 0.60 number of lesions |
|---|
| Least Square Mean (LS mean) | 0.37 (95% CI 0.18–0.76) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.